Core Viewpoint - Haixi New Drug (02637) has seen a significant stock price increase, reaching a new high of 145.9 HKD, which is nearly 70% higher than its IPO price of 86.4 HKD [1] Company Overview - Haixi New Drug is a commercial-stage pharmaceutical company with 15 approved generic drug products covering various therapeutic areas, including digestive, cardiovascular, endocrine, and nervous systems [1] - Since 2021, four core generic drugs have been included in the national drug procurement program, contributing over 90% of the company's revenue, projected to reach 425 million CNY in 2024 [1] Research and Development Pipeline - The company is also developing innovative drugs, including C019199, an immunotherapy targeting CSF-1R/DDR1/VEGFR2, currently in I/II clinical stages for indications like osteosarcoma and tenosynovial giant cell tumor, with plans to start a Phase III trial in the second half of 2025 [1] - Another drug, HXP056, is an oral treatment for wet age-related macular degeneration, expected to complete its Phase I clinical trial by the end of 2025 [1]

Core Insights - As of November 10, a total of 108 stocks reached their 52-week highs, with notable performers including Taijin Holdings (08321), OKURA HOLDINGS (01655), and Hejia Holdings (00704) achieving high rates of 125.00%, 84.90%, and 53.57% respectively [1] Summary by Category 52-Week Highs - Taijin Holdings (08321) closed at 0.620 with a peak price of 0.900, marking a 125.00% increase - OKURA HOLDINGS (01655) reached a closing price of 0.280 and a high of 0.355, reflecting an 84.90% rise - Hejia Holdings (00704) had a closing price of 0.345 and a peak of 0.430, showing a 53.57% increase - Other notable stocks include Sanhe Chemical (00301) with a 41.67% increase and Aide New Energy (02623) with a 36.25% rise [1] 52-Week Lows - Wangshan Wangshui-B (02630) recorded a closing price of 52.850 and a low of 51.000, resulting in a -21.84% decrease - Eight Horses Tea (06980) had a closing price of 52.850 and a low of 51.100, reflecting a -10.98% decline - New Enjoy Times (08519) reached a low of 0.270, marking a -10.00% drop - Other significant declines include Jiujiang Bank (06190) at -8.99% and Kun Group (00924) at -6.98% [3][4]

Group 1: Hong Kong Stock Exchange Performance - Hong Kong Stock Exchange reported total revenue of HKD 21.851 billion for the first three quarters, a year-on-year increase of 37% [1] - Main business income reached HKD 20.438 billion, up 41% year-on-year, while net profit was HKD 13.419 billion, reflecting a 45% increase [1] - The exchange achieved record highs in revenue and profit for the third consecutive quarter, indicating strong market activity and operational efficiency [1] Group 2: Biopharmaceutical Company Performance - Biopharmaceutical company Wangshan Wangshui-B saw a significant increase of 154.72% in the dark market, closing at HKD 85 per share [2] - The company focuses on discovering, developing, and commercializing small molecule drugs in the fields of neuropsychiatry and reproductive health [2] - The surge in dark market trading highlights strong market interest in the biopharmaceutical sector, particularly in neuropsychiatry and reproductive health treatments [2] Group 3: Electric Vehicle Company IPO - Seres (09927.HK) became the largest IPO for a Chinese automotive company in Hong Kong, raising over HKD 14 billion [3] - The company attracted 22 cornerstone investors and issued 108.6 million shares at a price of HKD 131.5 each [3] - The successful listing reflects the strong momentum in China's electric vehicle industry and positive market expectations for high-growth companies [3] Group 4: Instant Noodle Company Stock Performance - Master Kong Holdings (00322.HK) saw its stock price rise over 4%, closing at HKD 11.86, marking a new high since July [4] - Goldman Sachs reported that the company's profit targets are likely to be met, driven by pricing strategies, cost advantages, efficiency improvements, and strict promotional management [4] - The strong stock performance indicates optimistic market sentiment regarding the company's profitability outlook [4]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 福建海西新藥創制股份有限公司 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02637 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 78,707,270 | RMB | | | 1 RMB | | 78,707,270 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 78,707,270 | RMB | | | 1 RMB | | 78,707,270 | 本月底法定/註冊股本總額： RMB ...

Group 1 - The Hang Seng Index rose by 0.54%, gaining 141 points to close at 26,487 points, while the Hang Seng Tech Index increased by 0.31%. The morning trading volume in Hong Kong stocks reached HKD 178.7 billion [1] - Newly listed stock Dipu Technology (01384) surged by 36%, while Baima Tea (06890) rose over 8%, and Haixi New Drug (02637) increased by 7.59% [2] - The demand for energy storage driven by AI is expected to increase significantly, with CITIC Securities forecasting that total lithium battery demand will exceed 2,700 GWh next year, a year-on-year growth rate of over 30%. Energy storage battery demand is projected to exceed 900 GWh, leading to potential shortages in various lithium sectors [2] Group 2 - Ganfeng Lithium (01772) rose over 12%, and Tianqi Lithium (09696) increased by over 8% due to the strong performance of lithium mining stocks [2] - The energy storage sector saw significant gains, with Zhongchu Innovation (03931) rising over 12%, CATL (03750) increasing by 2.59%, and Shuangdeng Co. (06969) gaining over 7% [2] - Ruipu Lanjun (00666) increased by over 8% after the company launched several strategic new products covering energy storage, commercial vehicles, and passenger cars [3] Group 3 - Aneng Logistics (09956) surged by 22% following a privatization proposal from a major shareholder's consortium, with a premium rate exceeding 48% [4] - China Duty Free Group (01880) rose by 3% as the entire Hainan island is set to close in December, which is expected to boost the overall development of Hainan's tourism retail market [5] - China Hongqiao (01378) increased by nearly 7% due to recent production cuts in overseas electrolytic aluminum, which may further widen the supply-demand gap in the electrolytic aluminum market [6] Group 4 - Anjii Food (02648) rose over 8% with a 11.8% year-on-year growth in net profit attributable to shareholders in the third quarter, supported by a collaborative development across all channels [7] - The engineering machinery sector saw significant gains, with September exports continuing to grow year-on-year, and leading companies like Sany Heavy Industry (06031) rising by 9%, Senson International (02155) increasing by 8.02%, and China National Heavy Duty Truck Group (03808) gaining 3.7% [7] Group 5 - WuXi AppTec (02359) fell over 4% as the actual controller's shareholders plan to reduce their holdings by no more than 2% of the company's A-shares [8]

Core Viewpoint - Haixi New Drug (02637.HK) experienced a significant price increase, rising over 12% at one point, reaching a high of 114.9 HKD, which is more than a 30% increase from its IPO price of 86.4 HKD [1] Summary by Category - **Stock Performance** - As of the latest update, Haixi New Drug's stock is up 9.2%, trading at 111.6 HKD with a transaction volume of 20.93 million HKD [1]

Core Viewpoint - Haixi New Drug (02637) experienced a significant stock price increase, rising over 12% to a peak of 114.9 HKD, which is more than 30% above its IPO price of 86.4 HKD, indicating strong market interest and investor confidence in the company [1] Company Overview - Haixi New Drug is a commercial-stage pharmaceutical company that integrates research and development, production, and sales capabilities [1] - The company has received approval for 15 generic drug products, with a product portfolio that spans multiple therapeutic areas, including the digestive system, cardiovascular system, endocrine system, and nervous system [1] - Haixi New Drug has established a pipeline of four innovative drugs under development, targeting diseases in oncology, ophthalmology, and respiratory systems [1] Future Plans - The company plans to actively explore collaboration opportunities with multinational corporations (MNCs) to enhance its international clinical research and commercialization capabilities [1]

Core Viewpoint - Haixi New Drug (02637) has seen a significant stock price increase, rising over 12% at one point and currently trading at 111.6 HKD, which is more than 30% above its IPO price of 86.4 HKD [1] Company Overview - Haixi New Drug is a commercial-stage pharmaceutical company that integrates research and development, production, and sales capabilities [1] - The company has 15 approved generic drug products covering multiple therapeutic areas, including the digestive system, cardiovascular system, endocrine system, and nervous system [1] - Haixi New Drug has established a pipeline of four innovative drugs under development, targeting cancer, ophthalmology, and respiratory diseases [1] Future Plans - The company plans to actively explore collaboration opportunities with multinational corporations (MNCs) to enhance its international clinical research and commercialization capabilities [1]

Group 1 - The core viewpoint of the article highlights the successful debut of Haixi New Drug on the Hong Kong Stock Exchange, marking it as the first pharmaceutical company from Fujian to enter the Hong Kong market [1] - Haixi New Drug opened at 102 HKD, a rise of 18.06% from its issue price of 86.4 HKD, and closed at 104.2 HKD, representing a total increase of 20.6% [1] - The company's market capitalization reached 7.003 billion HKD following its first trading day [1] Group 2 - Haixi New Drug operates as a comprehensive biopharmaceutical enterprise, focusing on both generic and innovative drugs, with a robust product pipeline in various therapeutic areas including oncology and respiratory diseases [1] - The company has received approval for 15 generic drugs and has 4 innovative drugs in development, along with 37 global patents, showcasing its strong R&D capabilities [1] - The establishment of Haixi New Drug is part of a broader initiative by Fujian Province to develop its biopharmaceutical industry, which has been designated as a strategic emerging industry since 2009 [2]

Core Viewpoint - Fujian Haixi New Drug Creation Co., Ltd. (referred to as "Haixi New Drug") was listed on the Hong Kong Stock Exchange, with a closing price of 104.20 HKD on the first day, reflecting a 20.60% increase, but it dropped to 101.5 HKD the following day, a decrease of 2.59% [1]. Summary by Sections Share Issuance and Capital Structure - The total number of shares issued under the global offering was 11,500,000 H-shares, with 1,150,000 H-shares available for public offering and 10,350,000 H-shares for international offering [2]. - At the time of listing, the total number of shares issued was 78,707,270 [2]. Pricing and Proceeds - The final offering price was set at 86.40 HKD, resulting in total proceeds of 993.60 million HKD. After deducting estimated listing expenses of 53.47 million HKD, the net proceeds amounted to 940.13 million HKD [4][5]. Use of Proceeds - Approximately 52.0% of the net proceeds is expected to be used for ongoing investment in research and development to advance the drug pipeline and enrich the product portfolio. About 23.0% is anticipated for enhancing R&D capabilities and seeking collaboration opportunities. Additionally, 8.0% is planned for strengthening commercialization capabilities and expanding market influence, while 7.0% is allocated for improving and optimizing R&D and production systems, and 10.0% for working capital and other general corporate purposes [6]. Company Overview - Haixi New Drug is a commercial-stage pharmaceutical company that integrates R&D, production, and sales capabilities, with a pipeline of innovative drugs under development [6]. Financial Performance - The company's revenues for the years 2022, 2023, 2024, and the first five months of 2025 were 212.5 million, 316.6 million, 466.7 million, and 249.2 million RMB, respectively. The net profits for the same periods were 69.0 million, 117.5 million, 136.1 million, and 90.2 million RMB [7][8]. - The net cash flow from operating activities for the same periods was 85.3 million, 147.1 million, 163.9 million, and 80.1 million RMB [9]. Research and Development Pipeline - As of July 2025, Haixi New Drug has only four innovative drugs in the pipeline, all in early clinical stages. These include a multi-mechanism immune modulator C019199 for treating osteosarcoma and other malignancies, an oral small molecule drug HXP056 recently approved for clinical trials targeting wet age-related macular degeneration, and two other drugs for tumors and respiratory diseases still in preclinical research [10].